CytRx announces patient dosing in Phase 2 GBM study

CytRx (CYTR) announces the dosing of the first patient in a Phase 2 study of aldoxorubicin in unresectable GBM.

Preliminary results expected in H2.

The company says that if the results are positive, CYTR "will pursue the rapid development of aldoxorubicin for unresectable GBM, including filing for breakthrough therapy designation." (PR)

CYTR +5% premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs